Welcome!

News Feed Item

Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)

DUBLIN, March 13, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/jdzmv4/nasal_drug) have announced the addition of the "Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)" conference to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The Nasal Drug Delivery Conference will take place on the 3rd & 4th April 2014 at the Rembrandt Hotel, London

THREE REASONS TO ATTEND THIS EVENT

- Gain an update on the very latest scientific developments and technology advances in this field.

- Hear from an unrivaled panel of expert speakers.

- An excellent networking opportunity to build business relationships.

WHO SHOULD ATTEND

Managing Directors, Medical Directors, Head of Regulatory Affairs and Quality Assurance, Senior Executives in Research and Development, Registration, Marketing and all departments that may be involved in Nasal Drug Delivery, or who wish to understand the potential of this alternative therapeutic route. Those already involved in Nasal Drug Delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in Nasal Drug Delivery or are just considering the potential, this conference is an excellent route to understanding all aspects from the basic physiology through to launching a successful product. 

CHAIRPERSON: Dr Rene Bommer

KEYNOTE SPEAKER: Prof. Michael S Benninger

DATES:

3 & 4 April 2014

TIMES:

3 April 2014: Start 09.30 - Finish 17.30
Drinks Reception: Start 17.30 - Finish 18.30
4 April 2014: Start 09.15 - Finish 16.30

REGISTRATION & COFFEE

3 April 2014 09.00

VENUE & ACCOMMODATION

The Rembrandt Hotel, 11 Thurloe Place, London SW7 2RS

DIRECTIONS:

Opposite V&A Museum. Nearest underground station: South Kensington.

NOTE: Events may be cancelled due to commercial or organisational reasons. In this case Research and Markets will refund all registration fees which have already been paid. Research and Markets will not refund any charges arising from the participant having to cancel or re-book transportation or accommodation which he or she has arranged 

Key Topics Covered: 

DAY ONE - 3 April 2014

09.30 u Chairman's Welcome and Introduction
Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 1: Advances in Drug Therapies: State of the Art

09.45 u Nasal Drugs to Treat Nasal Disorders; A Comprehensive Review

- Anatomy and physiology
- Nasal disorders
- Treatment options and future prospects to treat allergic and non-allergic Rhinitis
- Rhinosinusitis and Polyps

Professor Michael S. Benninger, Chairman, The Head and Neck Institute, Professor of Surgery, Lerner College of Medicine, The Cleveland Clinic, USA 

10.45 - Discussion 

11.00 - Coffee

Session 2: Progress in Local and Systemic Nasal Drug Delivery

11.30 - Particulate Systems for Nasal (Vaccine) Delivery

- Literature review on particulate systems for nasal delivery
- Nanoparticulate systems for direct uptake
- Particle requirements for nasal deposition
- Modification of particle surface/particle engineering
- Formulation design
- Implications in nasal vaccine development

Dr Regina Scherliess, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany

12.10 - Antiviral Polymers - A Novel Concept of Intranasal Therapy Against Respiratory Viruses

- Marinomed has developed a technology for creating a protective physical barrier in the nasal cavity with antiviral polymers for the prevention and therapy of common cold and influenza

- Independent clinical trials in adults and children demonstrated that the intranasal administration of Iota-Carrageenan significantly reduced the time to disease clearance of patients with common cold and decreased the virus load in nasal lavages

- The existing product portfolio will be expanded and the new developments focus on combination products for the treatment of influenza and the prevention of virally-induced exacerbations in allergic patients 

Dr Angelika Bodenteich, Head of Development, Marinomed Biotechnologie, GmbH, Germany

12.50 - Discussion

13.00 - Lunch

14.00 - Nasal Drug Delivery - The Technology Whose Potential Has Not Yet Been Valorised

- Current technologies for nasal drug delivery
- Nasal application for unmet medical needs
- Factors affecting bioavailability and response after nasal application
- Symbiosis of formulation and device
- Identification of potential obstacles in product development

Dr Claudia Mattern, Adjunct Professor Nova Southeastern University, US-FL, Chief Scientific Officer, M & P Pharma AG, Switzerland 

Session 3: Nasal Devices, Device Testing and New Technologies

14.40 - Review of Nasal Drug Delivery Devices

- Business aspects
- Device technologies and nasal delivery systems
- Regulatory aspects
- Nasl spray characterisation 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

15.20 - Discussion 

15.30 - Tea

16.00 - New Trends in Nasal Delivery with Dry Powder Formulations

- Dry powder formulations represent attractive alternatives to liquid formulations

- Systemic delivery via the nasal cavity, including pain treatments and also intra-nasal vaccination, are being investigated and developed with dry powder formulation because it offers a number of benefits like thermal and microbiologic stability and the variability of the physico-chemical properties

- Regulatory Aptar pharma offers a line of disposable primeless devices designed specifically for liquid and for dry powder formulations

- Opportunities and case studies using our Unit Dose Powder, Single Dose Device technology platform

Holger Kehrer, Business Support Manager, Aptar pharma, France 

16.40 - Update on Advancia: Innovative Design Solution to Respond to New Challenges in Nasal Delivery

- Recent trends in nasal spray delivery
- Compliance, efficiency, convenience and ease of use of nasal delivery devices
- Regulatory requirement changes for nasal delivery requiring next generation devices

Pascale Farjas, Global Category Manager, Rexam Healthcare, France 

17.20 - Discussion 

17.30 - Close of Day One

17.30 - 18.30 Drinks Reception for Delegates and Speakers

DAY TWO - 4 April 2014

09.15 - Chairman's Review of Day One 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 4: Nasal Devices, Device Testing and New Technologies (continued)

09.30 - Current Nasal Powder Technologies: The Challenge of Powder Dosing

- Dosing requirements (dosing range, target to be filled, powder properties)
- Overview dosing systems (design, functionality)
- Examples of filling equipment (developmental equipment)
- Systems for fill weight verification (IPC, PAT,..)

Marco Laackmann, Division Leader, Inhalation, Harro Höfliger, Germany 

10.10 - Addressing Technical Barriers in Nasal Dry Powder Delivery 

- Patient / user needs - clinical trials, comfort, understanding
- Device requirements - materials, regulatory, risks
- Formulation requirements - dosage, residence time, stability
- Product performance - deposition, particle size distribution, plume geometry, shelf life
- Commercialisation - competition, cost, IP, market need, regulatory acceptance, USP

Ian Harrison, Chief Scientific Officer, Alchemy Pharmatech, UK 

10.50 - Discussion

11.00 - Coffee

11.30 - How Technology Can be Used to Enhance our Understanding of User Behaviour and Influence the Way we Conduct User Research

- Social Intelligence for greater product understanding
- Gaining access to the right study participants
- Field research from your desk
- Quantifying human performance
- Seeing through our users eyes
- Understanding emotional responses and states of mind

Miranda Newberry, Human Factors Consultant, PA Consulting, UK

12.10 - A Platform Approach to Developing Patient Oriented Drug Delivery Systems and Products

- This approach to the development of drug delivery technology solutions is unconventional, risky and offers tremendous potential for developing drug/device combination products that deliver unparalleled value to both the patient and the manufacturer

- This well-executed platform based approach seeks to reduce the complexity of developing new combination products without sacrificing innovation

- Progress of Mystic's drug delivery platform solutions, its capabilities, applications and the benefits for patients and Pharma/biotech manufacturers
Timothy Sullivan, President & CEO, Mystic Pharmaceuticals Inc., USA (invited)

12.50 - Discussion

13.00 - Lunch

Session 5: Regulatory Requirements

14.00 - EU Regulatory Requirements 

- Differences between pulmonary and nasal requirements
- Bio-equivalence Representative from a Regulatory Agency, (invited)

14.40 - Discussion

Session 6: Business and Intellectual Property (IP) in Nasal Systemic Drug Delivery

14.50 - Choosing the Best Way to Finance Your Company 

- First: get the business model right
- Starting out - is there easy money?
- Angels vs Dragons
- Dilutive vs non-dilutive financing
- Financing through partnering
- Planning an exit - IPO vs Trade Sale

Finton Walton, CEO, Pharma Ventures, UK

15.30 - R&D Collaborations for Drug Delivery: Legal and Contractual Issues

- The different priorities of universities, start-ups and major companies
- Benefits of term sheets / letters of intent and how to use them
- Defining the scope of the collaboration: work, field, etc.
- IP ownership and licences
- Other legal issues

Mark Anderson, Solicitor, Anderson Law LLP, UK

16.10 u Discussion

16.20 u Chairman's Concluding Remarks

16.30 u Close of Conference and Tea 

For more information visit http://www.researchandmarkets.com/research/jdzmv4/nasal_drug

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
SYS-CON Events announced today that Outscale will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outscale's technology makes an automated and adaptable Cloud available to businesses, supporting them in the most complex IT projects while controlling their operational aspects. You boost your IT infrastructure's reactivity, with request responses that only take a few seconds.
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
SYS-CON Events announced today that DivvyCloud will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. DivvyCloud software enables organizations to achieve their cloud computing goals by simplifying and automating security, compliance and cost optimization of public and private cloud infrastructure. Using DivvyCloud, customers can leverage programmatic Bots to identify and remediate common cloud problems in rea...
SYS-CON Events announced today that Tintri, Inc, a leading provider of enterprise cloud infrastructure, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Tintri offers an enterprise cloud platform built with public cloud-like web services and RESTful APIs. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds – to build agile development environments...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs ofte...
SYS-CON Events announced today that Tappest will exhibit MooseFS at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. MooseFS is a breakthrough concept in the storage industry. It allows you to secure stored data with either duplication or erasure coding using any server. The newest – 4.0 version of the software enables users to maintain the redundancy level with even 50% less hard drive space required. The software func...
SYS-CON Events announced today that Interoute has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Interoute is the owner operator of Europe's largest network and a global cloud services platform, which encompasses over 70,000 km of lit fiber, 15 data centers, 17 virtual data centers and 33 colocation centers, with connections to 195 additional partner data centers. Our full-service Unifie...
SYS-CON Events announced today that EARP will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "We are a software house, so we perfectly understand challenges that other software houses face in their projects. We can augment a team, that will work with the same standards and processes as our partners' internal teams. Our teams will deliver the same quality within the required time and budget just as our partn...
SYS-CON Events announced today that Carbonite will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Carbonite protects your entire IT footprint with the right level of protection for each workload, ensuring lower costs and dependable solutions with DoubleTake and Evault.
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...